The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology, for post-traumatic stress disorder.

The trial is being led by principal investigator Matthew Rizzo, MD, FAAN, FANA, Frances & Edgar Reynolds chair, professor of the UNMC Department of Neurological Sciences, chief physician for neurological services at Nebraska Medicine, and chief physician for neurosciences clinical programs at Nebraska Medicine.

“We are very excited to have this important trial underway,” stated Dr. Rizzo. “Our …

Full story available on